ClinicalTrials.gg
RecruitingNCT05967819FHAUpdated Jan 8, 2026

Effects of Physical and Psychosocial Stress on Functional Hypothalamic Amenorrhea in Exercising Women

An interventional study of Exercise Stress and Psychosocial Stress in Amenorrhea Secondary, sponsored by University of Colorado, Colorado Springs. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by University of Colorado, Colorado Springs · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Amenorrhea with a site in United States — 7 open to participants now, 9 under way, 1 of them phase 3. Amenorrhea · United States.

Planned enrollment
13th of 30
54 · median 37
Started
2023
with 1 other
No phase
8 of 43
1 open now
Registered
37th of 43
by date

Among the 43 studies in Amenorrhea with a site in United States, this one is the 13th largest by planned enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2023, is one of 8 with no phase, and was the 37th registered.

Amenorrhea

80 studies on the registry are indexed under Amenorrhea; 17 are open to participants now.

Browse Amenorrhea studies →

Open to participants now

7 of the 43 studies in Amenorrhea with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Amenorrhea studies recruiting now, none (0%) set no upper age limit and 11 (85%) stop at 75 or younger; 8 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Amenorrhea with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine how changes in exercise and psychosocial stress may influence the risk of menstrual cycle irregularities in female runners and cyclists. The main questions it aims to answer are:

  • Does the implementation of exercise or psychosocial stress effect circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length?
  • Is there an additive effect of combined exercise and psychosocial on circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length?

Participants will be asked to do the following over the \~3 month enrollment period:

  • attend a laboratory visit at the beginning and end of the study to have their resting metabolic rate, aerobic fitness, and body composition tested
  • monitor their menstrual cycle length, daily perceived stress levels, physical activity, and diet each month
  • provide several urine and saliva samples each month
  • either maintain their usual physical activity and lifestyle habits (control group), increase the duration of their weekly running or cycling mileage by 30% (exercise stress group), complete cognitive function tasks designed to be stressful (psychosocial stress group), or increase the duration of their weekly running or cycling mileage by 30% and complete cognitive function tasks designed to be stressful (exercise + psychosocial stress group) during the final month of enrollment.

Researchers will compare control, exercise stress, psychosocial stress, and exercise + psychosocial stress groups to see if there is an effect on circulating reproductive hormones (i.e., estradiol, progesterone, luteinizing hormone) and menstrual cycle length.

03

Conditions studied

  • Amenorrhea Secondary

Browse trials for

Keywords

  • functional hypothalamic amenorrhea
  • menstrual cycle
  • female athlete
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participates in structured running or cycling exercise for at least 30 minutes on 4 days per week or more
  • have regular periods every 21 to 35 days
  • have not used hormonal for at least the past 6 months
  • are not currently or trying to become pregnant or are breastfeeding, and have not been pregnant or breastfeeding for the past 12 months
  • have never been diagnosed with a menstrual cycle disorder (e.g., menorrhagia, amenorrhea, dysmenorrhea, polycystic ovary syndrome [PCOS], endometriosis, premenstrual dysphoric disorder [PMDD], menstrual migraines, ovarian cancer, ovarian insufficiency, uterine or endometrial cancer)
  • have never been diagnosed with a metabolic disease (e.g., hypothyroidism, hyperthyroidism, Cushing disease, Addison's disease, diabetes)

Exclusion criteria

Exclusion Criteria:

  • missing > 4 consecutive days of aerobic exercise (i.e., running, cycling, cross training) if assigned to the exercise intervention groups
  • they indicate they "Could not participate at all due to a health problem" or have had to modify their exercise training, felt their injury, illness, or other health problem has affected their exercise performance, or experienced symptoms/ health complaints greater than "To a minor extent" on the Oslo Sports Trauma Research Center Questionnaire (exercise training intervention group)
  • demonstrate clinical low energy availability as defined as energy availability \<30 Kcal/kg fat free mass in the first two months of at-home monitoring
  • report menstrual cycle lengths \<21 days or >35 days in the first two months of at-home monitoring
  • do not demonstrate an anticipated rise in progesterone levels during the latter half of their cycle and luteinizing hormone levels at mid-cycle compared to tests taken during the first few days after menses in the first two months of at-home monitoring
  • begin taking a hormonal
  • become pregnant
  • are diagnosed with a menstrual cycle disorder (e.g., menorrhagia, amenorrhea, dysmenorrhea, polycystic ovary syndrome [PCOS], endometriosis, premenstrual dysphoric disorder [PMDD], menstrual migraines, ovarian cancer, ovarian insufficiency, uterine or endometrial cancer)
  • are diagnosed with a metabolic disease (e.g., hypothyroidism, hyperthyroidism, Cushing disease, Addison's disease, diabetes), 10) are diagnosed with a major cardiovascular disease, respiratory disease, or musculoskeletal injury
  • are unable to follow instructions for any of the procedures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • No intervention
    Control

    Participants will be asked to maintain their usual physical activity and lifestyle habits.

  • Experimental
    Exercise Stress

    The duration of participant's weekly running or cycling mileage will be increased by 30% while intensity is maintained.

    Behavioral: Exercise Stress

  • Experimental
    Psychosocial Stress

    Participants will be asked to complete cognitive function tasks designed to be stressful while maintaining their usual physical activity habits.

    Behavioral: Psychosocial Stress

  • Experimental
    Exercise + Psychosocial Stress

    Participants will be asked to complete cognitive function tasks designed to be stressful while the duration of their weekly running or cycling mileage is increased by 30% and intensity maintained.

    Behavioral: Exercise Stress · Behavioral: Psychosocial Stress

Interventions

  • BehavioralExercise Stress

    Increased exercise volume

  • BehavioralPsychosocial Stress

    cognitive tasks

06

What researchers measure

Primary outcomes

  1. Urinary estrone-3-glucuronide (E3G)

    ng/mL

    Time frame: 3 months

  2. Urinary pregnanediol glucuronide (PdG)

    ug/mL

    Time frame: 3 months

  3. Urinary luteinizing hormone (LH)

    MIU/mL

    Time frame: 3 months

  4. Menstrual cycle length

    days

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
  • University of Colorado Colorado Springs
    Colorado Springs, Colorado 80918, United States
    Recruiting
    • Marissa Baranauskas, PhD · Contactmbaranau@uccs.edu · 719-255-4475
    • Kristen Rudd, PhD · Contactkrudd@uccs.edu
    • Marissa Baranauskas, PhD · Principal investigator
    • Kristen Rudd, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Aug 2026, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartActual
Aug 9, 2023
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Jan 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967819
Lead sponsor
University of Colorado, Colorado Springs
Responsible party
Marissa Baranauskas (Assistant Professor, University of Colorado, Colorado Springs) — Principal investigator
First posted
Aug 1, 2023
Start date
Aug 9, 2023
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Marissa Baranauskas, PhD
Contact
mbaranau@uccs.edu
719-255-4475
Kristen Rudd, PhD
Contact
krudd@uccs.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion